As of 2024-12-14, the Relative Valuation of Aclaris Therapeutics Inc (ACRS) is (12.51) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.22 USD, the upside of Aclaris Therapeutics Inc based on Relative Valuation is -488.5%.
The range of the Relative Valuation is (11.59) - (12.97) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.4x - 25.0x | 23.2x |
| Forward P/E multiples | 22.4x - 26.2x | 25.2x |
| Fair Price | (11.59) - (12.97) | (12.51) |
| Upside | -460.1% - -502.9% | -488.5% |
| Date | P/E |
| 2024-12-11 | -6.83 |
| 2024-12-10 | -7.01 |
| 2024-12-09 | -7.55 |
| 2024-12-06 | -7.61 |
| 2024-12-05 | -7.35 |
| 2024-12-04 | -7.26 |
| 2024-12-03 | -7.42 |
| 2024-12-02 | -7.64 |
| 2024-11-29 | -7.86 |
| 2024-11-27 | -7.37 |
| 2024-11-26 | -7.01 |
| 2024-11-25 | -7.70 |
| 2024-11-22 | -7.34 |
| 2024-11-21 | -8.34 |
| 2024-11-20 | -7.64 |
| 2024-11-19 | -8.86 |
| 2024-11-18 | -6.06 |
| 2024-11-15 | -3.96 |
| 2024-11-14 | -4.21 |
| 2024-11-13 | -4.71 |
| 2024-11-12 | -4.94 |
| 2024-11-11 | -5.08 |
| 2024-11-08 | -5.10 |
| 2024-11-07 | -4.73 |
| 2024-11-06 | -4.36 |
| 2024-11-05 | -4.29 |
| 2024-11-04 | -4.19 |
| 2024-11-01 | -4.03 |
| 2024-10-31 | -3.49 |
| 2024-10-30 | -3.47 |
| 2024-10-29 | -3.30 |
| 2024-10-28 | -3.11 |
| 2024-10-25 | -3.26 |
| 2024-10-24 | -2.49 |
| 2024-10-23 | -2.43 |
| 2024-10-22 | -2.45 |
| 2024-10-21 | -2.34 |
| 2024-10-18 | -2.30 |
| 2024-10-17 | -2.26 |
| 2024-10-16 | -2.24 |
| 2024-10-15 | -2.28 |
| 2024-10-14 | -2.32 |
| 2024-10-11 | -2.28 |
| 2024-10-10 | -2.24 |
| 2024-10-09 | -2.26 |
| 2024-10-08 | -2.24 |
| 2024-10-07 | -2.22 |
| 2024-10-04 | -2.30 |
| 2024-10-03 | -2.30 |
| 2024-10-02 | -2.26 |